BioNTech SE is a biotechnology company that develops immunotherapies for cancer, infectious diseases, and other serious conditions. The company's core expertise lies in messenger RNA (mRNA) therapeutics, engineered cell therapies, and targeted antibodies. BioNTech operates a multi-platform strategy, utilizing its mRNA technology to instruct the immune system to target specific diseases.
The majority of BioNTech's revenue is generated from the commercialization of Comirnaty, the mRNA-based COVID-19 vaccine co-developed and marketed globally in partnership with Pfizer. As pandemic-related vaccine demand has normalized, the company is directing its capital toward its oncology pipeline. BioNTech's clinical programs include individualized neoantigen specific immunotherapies (iNeST), off-the-shelf mRNA cancer vaccines, CAR-T cell therapies, and immunomodulators such as bispecific antibodies targeting PD-L1 and VEGF-A.
Geographically, BioNTech is headquartered in Mainz, Germany, and operates globally with research, development, and manufacturing facilities across Europe, the United States, Asia, and Africa. The company maintains strategic collaborations with major pharmaceutical companies, academic institutions, and research organizations to advance its clinical pipeline. BioNTech's competitive position is anchored by its mRNA platform, manufacturing capabilities, and a diversified pipeline aimed at oncology and infectious diseases.
